Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Clinical trial NCT04108858 · TERMINATED
Trial details
- NCT number
- NCT04108858
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-20
- Primary completion
- 2022-04-29
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.